ライフサイエンスコーパス: constipation

1 the search terms 'Parkinson's disease' and 'constipation'.

2 7.5% for incontinence and 15.6% vs 54.0% for constipation).

3 line for the management of acute and chronic constipation).

4 nisms, evaluation, and management of chronic constipation.

5 herapies in patients with chronic idiopathic constipation.

6 ntent in a loperamide-induced mouse model of constipation.

7 concern but prioritized pain management over constipation.

8 psychomotor impairment, nausea/vomiting, and constipation.

9 e gold standards for chronic and sub-chronic constipation.

10 r infrequency of defecation as a hallmark of constipation.

11 rnate therapeutic strategy in treating their constipation.

12 h chronic non-cancer pain and opioid-induced constipation.

13 n and significantly reduced morphine-induced constipation.

14 mediates the prolonged effect of morphine on constipation.

15 associated with delayed colonic transit and constipation.

16 with motor and non-motor symptoms, including constipation.

17 potential treatments for age-related chronic constipation.

18 ive minutes, are also reliable indicators of constipation.

19 dulator of morphine-related inflammation and constipation.

20 thout major side effects such as sedation or constipation.

21 nstipation and irritable bowel syndrome with constipation.

22 its therapeutic efficacy in mouse models of constipation.

23 and contribute to the development of chronic constipation.

24 effects, such as respiratory depression and constipation.

25 transient, IBS-like symptoms but no sign of constipation.

26 kinson's disease compared with those without constipation.

27 a more comprehensive approach to diagnosing constipation.

28 yndrome, functional dyspepsia, or functional constipation.

29 lyethylene glycol alone in the management of constipation.

30 the use of polyethylene glycol in functional constipation.

31 aspects of fecal control (P < 0.05), except constipation.

32 colonic mucosal microbiota of patients with constipation.

33 ane production (measured in breath), but not constipation.

34 ch may be associated with the development of constipation.

35 (IBS-C) should be preliminarily treated for constipation.

36 isits in 2012; most of these visits were for constipation.

37 problems, to delays in gastric emptying and constipation.

38 nd to define the symptoms that best indicate constipation.

39 pation according to the Rome IV criteria for constipation.

40 onists are another option for opioid-induced constipation.

41 cacious for patients with chronic idiopathic constipation.

42 nt success rates in children with functional constipation.

43 e-based recommendations in the management of constipation.

44 ents should be counselled regarding possible constipation.

45 elusetrag) in adults with chronic idiopathic constipation.

46 nd 39.6% (95%CI: 37.5, 41.7) for sub-chronic constipation.

47 up were somnolence, sedation, dizziness, and constipation.

48 tion (19%), nausea (16%), fatigue (14%), and constipation (14%) as the most frequent adverse effects.

49 rders (27 with irritable bowel syndrome with constipation, 15 with functional bloating, and 3 with ir

50 six [6%] participants in the placebo group), constipation (16 [8%] vs 19 [9%] vs 0), nausea (16 [8%]

51 %] vs 10/109 [9%]), as was treatment-related constipation (16/92 [17%] vs 6/109 [6%]).

52 e of tremor (RR 7.59, 95% CI 1.11-44.83) and constipation (2.01, 1.62-2.49) was higher in those who w

53 .31), balance impairments (2.19, 1.09-4.16), constipation (2.24, 2.04-2.46), hypotension (3.23, 1.85-

54 lutamide were nausea (26 [14%] vs 33 [17%]), constipation (23 [13%] vs 25 [13%]), and arthralgia (18

55 ombocytopenia (32.2%), headache (29.4%), and constipation (26.5%).

56 re grade 1-4 anorexia (33 [28%] vs 10 [8%]), constipation (29 [25%] vs 11 [9%]), hypomagnesaemia (27

57 15.5] vs 9.5 [6.9 to 12.1]; p=0.013) and in constipation (-3.2 [-7.3 to 0.9] vs 1.8 [-2.4 to 6.0]; p

58 4.4%-4.8% for IBS, 7.9%-8.6% for functional constipation, 3.6%-5.3% for functional diarrhea, 2.0%-3.

59 of 109), loss of appetite, 50.5% (49 of 97), constipation 30.4% (21 of 69), pain 30.2% (29 of 96), an

60 re predominantly grade 1 or 2, most commonly constipation (31 [36%]), fatigue (29 [33%]), myalgia 21

61 (55%), dry mouth (45%), nail toxicity (35%), constipation (34%), decreased appetite (32%), and dysgeu

62 gastrointestinal toxicities (diarrhea [46%], constipation [41%], and nausea [38%]) and grade 3/4 cyto

63 (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and st

64 s (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting

65 n increase over placebo in both trials being constipation (6%-8% for preladenant vs 1%-3% for placebo

66 ment-related adverse event, mild to moderate constipation (6.3%) was the most common gastrointestinal

67 ory failure (11 [5%], 14 [7%], 11 [5%]), and constipation (7 [3%], 13 [6%], 10 [5%]).

68 acebo, were nausea (8.1% and 7.5% vs. 5.1%), constipation (7.4% and 8.6% vs. 2.5%), and abdominal pai

69 or distention, 1.1%-1.9% for opioid-induced constipation, 7.5%-10.0% for unspecified FBDs, and 28.6%

70 We diagnosed constipation according to the Rome IV criteria for const

71 Chronic constipation accounts for at least 8 million annual visi

72 cantly increased odds of maternally reported constipation (adjusted odds ratio [aOR], 2.7; 95% CI, 1.

73 ed with colonic transit before adjusting for constipation, age, body mass index, and diet; genera fro

74 received fecal microbiota from patients with constipation also upregulated SERT in Caco-2 cells.

75 Constipation among Asian adults was characterized by thr

76 a were 24.0% (95%CI: 22.1, 25.9) for chronic constipation and 39.6% (95%CI: 37.5, 41.7) for sub-chron

77 a 62-year old woman with functional chronic constipation and a 42-year old woman with travel plans.

78 with ASD, chronic right-sided fecal loading constipation and a slow versus fast response to therapy

79 r old male with multiple episodes of melena, constipation and abdominal pain for one year duration is

80 However, side effects, including persistent constipation and antinociceptive tolerance, limit its cl

81 ly 25% of patients diagnosed with idiopathic constipation and can be improved with different therapeu

82 s estimated using five simple definitions of constipation and compared with definitions based on the

83 05), and discriminated between patients with constipation and controls with 94% accuracy.

84 atients suffer from gastroesophageal reflux, constipation and delayed gastric emptying.

85 rapid eye movement sleep disorder, anosmia, constipation and depression) appear at prodromic/premoto

86 Secondly, to evaluate changes in symptoms of constipation and diarrhea, and Health related quality of

87 y women (controls) and 25 women with chronic constipation and evaluated by 16S ribosomal RNA gene seq

88 , but increases the prevalence of functional constipation and functional diarrhea.

89 early parasympathetic dysfunction leading to constipation and gastroparesis.

90 s study, fecal microbiota from patients with constipation and healthy controls were transplanted into

91 e management of acute and functional chronic constipation and how they affects their recommendations.

92 nd fecal microbiota in patients with chronic constipation and in healthy subjects to investigate the

93 search terms: bowel dysfunction, defecation, constipation and irrigation.

94 between constipation subtypes of functional constipation and irritable bowel syndrome with constipat

95 lyethylene glycol is commonly used to manage constipation and is available with or without electrolyt

96 s will increase the diagnostic confidence of constipation and its subtypes but more studies of the va

97 associated with motility disorders inducing constipation and loss of nitrergic myenteric neurons in

98 Phase I and II clinical trials of NT3 (for constipation and neuropathy) have shown that peripheral

99 essive straining as the biggest component of constipation and only a minority of patients with consti

100 ed ligands have been proposed to induce less constipation and respiratory depressant side effects tha

101 IBS-M may actually simply present functional constipation and should be managed as such.

102 Early development of constipation and urinary symptoms were associated with h

103 million (95% CI, 0.8-1.2) visits for chronic constipation, and 0.7 million (95% CI, 0.5-0.8) visits f

104 erance, dependence, respiratory suppression, constipation, and abuse liability detract from the gener

105 f nausea, sleep disturbance, skin reactions, constipation, and depression, with only skin reactions r

106 physical dependence, respiratory depression, constipation, and displayed no reward or aversion in CPP

107 opicapone vs placebo groups were dyskinesia, constipation, and dry mouth.

108 refill, Emergency Department (ED) visit for constipation, and ED visit for pain.

109 Nausea, vomiting, constipation, and headache were more common in the SXT a

110 tment-emergent adverse events being fatigue, constipation, and headache.

111 o lower incidence of overall adverse events, constipation, and least trial withdrawal rate.

112 Surprisingly, respiratory depression, constipation, and opioid withdrawal signs are unchanged

113 nd abdominal pain consistency and intensity, constipation, and paresthesias.

114 ents consider themselves able to self-manage constipation, and patients have often tried many differe

115 onstipation or irritable bowel syndrome with constipation, and with >2 features of impaired evacuatio

116 were fatigue, peripheral neuropathy, nausea, constipation, anorexia, diarrhea, and vomiting.

117 s of grade of severity for nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pa

118 rrhea (aOR, 2.3; 95% CI, 1.5-3.6; P < .001), constipation (aOR, 1.6; 95% CI, 1.2-2.3; P < .01), and f

119 Primarily, we found that certain symptoms of constipation are age-dependent.

120 Earlier urinary symptoms and constipation are associated with a more rapid disease pr

121 meta-analysis demonstrates that people with constipation are at a higher risk of developing Parkinso

122 Mood disorders and constipation are often comorbid, yet their shared etiolo

123 (GI) dysfunctions, such as gastroparesis and constipation, are prodromal to the cardinal motor sympto

124 IBS with predominant Diarrhea or Functional Constipation as might be expected.

125 sacodyl and sodium picosulfate and for acute constipation bisacodyl, sodium picosulfate and macrogol

126 ompared to the Rome III criteria for chronic constipation but an unacceptably low specificity (51.3%,

127 ion duration increased risk of ED visits for constipation, but not for pain or refill.

128 able for the treatment of chronic idiopathic constipation, but their relative efficacy is unclear bec

129 Studies were included if they assessed constipation by means of a structured questionnaire or i

130 disease compared with those without and that constipation can predate Parkinson's diagnosis by over a

131 According to Rome criteria, chronic constipation (CC) includes functional constipation (FC)

132 ue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin, but clinica

133 movement sleep behavior disorder, hyposmia, constipation), characteristic movement difficulty (eg, t

134 ons not previously reported (e.g., diabetes, constipation, cholelithiasis, short stature, failure to

135 s are not present, a diagnosis of functional constipation, chronic idiopathic constipation, or irrita

136 d in response to a meal, in 15 patients with constipation, chronically dependent on laxatives, 5 heal

137 ithm provided to evaluate chronic idiopathic constipation (CIC) that is refractory to available laxat

138 r, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs and symptoms

139 In the adult population, the management of constipation continues to evolve as well as the understa

140 food and water intake, Smn deficiency caused constipation, delayed gastric emptying, slow intestinal

141 In clinical practice, assessment of constipation depends on reliability, consistency and fre

142 GI symptoms were based on maternal report of constipation, diarrhea, and food allergy/intolerance.

143 six toxicities (anorexia, nausea, vomiting, constipation, diarrhea, and hair loss) within three rand

144 signs and symptoms including abdominal pain, constipation, diarrhea, nausea, vomiting, and flatulence

145 apy on the basis of the predominant symptom (constipation, diarrhoea, pain, or bloating) or combinati

146 e reason may be that the symptom patterns of constipation differ in different demographic groups.

147 ntidepressants suffered from abdominal pain, constipation, dizziness, and dry mouth.

148 AEs of nausea, headache, constipation, dizziness, and somnolence, each occurred i

149 tly than the placebo group, included nausea, constipation, dizziness, vomiting, somnolence, fatigue,

150 by means of a structured questionnaire or if constipation/drugs used to treat constipation were coded

151 rs have potential therapeutic indications in constipation, dry eye, cholestatic liver diseases, and i

152 in Tg mice reduced ENS aSyn aggregation and constipation, enhanced gut motility, and increased level

153 hronic constipation (CC) includes functional constipation (FC) and irritable bowel syndrome with cons

154 BACKGROUND & AIMS: Functional constipation (FC) is a common childhood problem often re

155 Functional constipation (FC) is a common childhood problem often re

156 : irritable bowel syndrome (IBS); functional constipation (FC); functional diarrhea (FDr); functional

157 rse events (>30%) included nausea, diarrhea, constipation, febrile neutropenia, fatigue, hypokalemia,

158 This issue provides a clinical overview of constipation, focusing on prevention, diagnosis, treatme

159 onic mucosa could discriminate patients with constipation from healthy individuals.

160 globus, rumination syndrome, IBS, bloating, constipation, functional abdominal pain, sphincter of Od

161 zil signal and disease duration, severity of constipation, gastric emptying time, and heart rate vari

162 d clinical information about motor severity, constipation, gastroparesis, and other parameters.

163 ntal defects cause vomiting, abdominal pain, constipation, growth failure, and early death.

164 Those with constipation had a pooled OR of 2.27 (95% CI 2.09 to 2.4

165 Fourteen patients with chronic constipation had slow colonic transit.

166 Different definitions of constipation have been used to estimate its prevalence i

167 ipation and only a minority of patients with constipation have infrequent bowel movements.

168 ICUs have developed bowel protocols to treat constipation; however, their effect on clinical outcomes

169 8), colour vision abnormalities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), a

170 nction, featured by orthostatic hypotension, constipation, hypohidrosis and hyposmia, without motor d

171 lder pain or stiffness), autonomic features (constipation, hypotension, erectile dysfunction, urinary

172 -predominant IBS (IBS-D), mixed-diarrhea-and-constipation IBS (IBS-M), and constipation-predominant (

173 Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastroin

174 Sixteen additional patients with IBS with Constipation (IBS-C) referred in the same period served

175 f having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C) should be preliminarily treated for

176 ation (FC) and irritable bowel syndrome with constipation (IBS-C).

177 D) or IBS with mixed pattern of diarrhea and constipation (IBS-M).

178 Surgery for pediatric idiopathic constipation (IC) is undertaken after failure of bowel m

179 ea reported in 24 (20.5%) and 19 (16.4%) and constipation in 22 (18.8%) and 15 (12.9%) patients treat

180 The prevalence of constipation in a large nationally representative sample

181 olytes are effective and safe treatments for constipation in adults.

182 olytes (PEG) in the management of functional constipation in adults.

183 adjuvant therapy for treatment of functional constipation in children and refutes recently published

184 of probiotics in the treatment of functional constipation in children have yielded conflicting result

185 Treatment for chronic constipation in older people is challenging and the cond

186 ay contribute to impaired micturition and/or constipation in Parkinson disease and other alpha-synucl

187 w option for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.

188 agonist, for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.

189 roaches and limitations in the management of constipation in the older ones to ease the gastroenterol

190 group and we found the highest prevalence of constipation in women and young adults (19.7 and 23.5%,

191 The most common adverse event was constipation (in 8.1% of patients receiving IW-3718 and

192 even, and seven patients, respectively), and constipation (in three, five, four, none, and seven pati

193 n has predicted efficacy in various types of constipation including that associated with cystic fibro

194 lonic mucosal microbiota was associated with constipation, independent of colonic transit (P < .05),

195 Opioid-induced constipation is a frequent side-effect of opioid treatme

196 Constipation is a frequently reported bowel symptom in t

197 Chronic constipation is a prevalent functional gastrointestinal

198 Functional constipation is a prevalent, burdensome gastrointestinal

199 Constipation is a recognised non-motor feature of Parkin

200 Constipation is a symptom that affects around 11-20% of

201 ed success rate of irrigation for functional constipation is about 50 %, comparable to or better than

202 Constipation is common among critically ill patients and

203 Chronic constipation is either a primary disorder (such as norma

204 Although constipation is not a physiologic consequence of normal

205 to polyethylene glycol for the management of constipation is not established.

206 nstipation, or irritable bowel syndrome with constipation is often made.

207 Constipation is often self-managed by patients and guide

208 With a worldwide prevalence of 15%, chronic constipation is one of the most frequent gastrointestina

209 rates of severe symptoms, including dyspnea, constipation, low appetite, fatigue, depression, and anx

210 ts, but the majority focused on diet-related constipation management.

211 We aimed at verifying if functional constipation may indeed lead to an erroneous diagnosis o

212 For specific patients, slow-transit constipation may necessitate a colectomy.

213 Constipation might be due to many different medical cond

214 Restricting analysis to studies assessing constipation more than 10 years prior to Parkinson's dis

215 at least one treatment suggested on chronic constipation, most frequently dietary changes, macrogol

216 plantar erythrodysesthesia (n = 62 [43.7%]), constipation (n = 56 [39.4%]), decreased appetite (n = 4

217 Risk of ED visit for constipation (n = 61, 1%) was increased with opioid pres

218 in (n = 96; 74.4%), anxiety (n = 77; 59.7%), constipation (n = 69; 53.5%), depression (n = 64; 49.6%)

219 osis (n=2), gastroenteritis viral (n=1), and constipation (n=1).

220 3%), alopecia (50%), elevated AST (50%), and constipation, nausea, and thrombocytopenia (42% each).

221 Moreover, we emphasize that symptoms of constipation not included in the Rome IV criteria, such

222 patients do not meet these criteria (No Rome Constipation, NRC).

223 testinal (diarrhoea, flatulence, nausea, and constipation) occurring in 16 (13%) patients with veveri

224 g mice had reduced aSyn aggregation and less constipation, occurring in part by increasing both pro-B

225 Opioid-induced constipation (OIC) has become increasingly prevalent wit

226 icle is a new sixth category, opioid induced constipation (OIC) which is distinct from the functional

227 their application, including opioid-induced constipation (OIC), respiratory depression, and addictio

228 These side effects include opioid-induced constipation (OIC), sedation, dizziness, and nausea.

229 r advance in the treatment of opioid-induced constipation (OIC).

230 esent to the gastroenterologist with chronic constipation on a background of colonic inflammation, we

231 sition of the fecal microbiota, but not with constipation or colonic transit.

232 s from patients with IBS-D (but not IBS with constipation or controls) had increased levels of MIR29A

233 orders are defined by >2 symptoms of chronic constipation or irritable bowel syndrome with constipati

234 syndrome, chronic functional abdominal pain, constipation, or diarrhea.

235 functional constipation, chronic idiopathic constipation, or irritable bowel syndrome with constipat

236 ominant symptom (IBS with diarrhea, IBS with constipation, or mixed IBS) plays an important role in s

237 ile there was no effect of gender, diarrhea, constipation, other chronic diseases and celiac disease

238 Self-reported constipation over the past 12 months had the highest sen

239 lly well, he reported having had progressive constipation, pelvic pressure, and narrow-caliber stools

240 Overall, in adults diagnosed with functional constipation per Rome III criteria, significant heteroge

241 PAC-QOL) in adults diagnosed with functional constipation per Rome III guidelines.

242 Differentially abundant taxa were linked to constipation, physical activity, possible RBD, smoking,

243 Physical activity, sex, constipation, possible rapid eye movement sleep behavior

244 e surgery alone but may increase the risk of constipation postoperatively.

245 d-diarrhea-and-constipation IBS (IBS-M), and constipation-predominant (IBS-C) relative to the control

246 isorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity

247 Symptom scores for constipation preoperatively and 2 year after RYGB were 1

248 received fecal microbiota from patients with constipation presented a reducing in intestinal peristal

249 An 87 years old male with history of chronic constipation presents with severe abdominal pain to the

250 ymptoms (PAC-SYM), and Patient Assessment of Constipation-Quality of Life (PAC-QOL) in adults diagnos

251 Rome III irritable bowel syndrome (IBS) and constipation questions, and the SF-8 quality of life que

252 In all patients with constipation, rectal outlet dysfunction should be exclud

253 Diagnosing constipation remains difficult and its treatment continu

254 r, causal relationship between dysbiosis and constipation remains poorly understood.

255 ence for its use in adult chronic functional constipation remains unclear.

256 ssociated with a trend toward a reduction in constipation (risk ratio, 0.50 [95% CI, 0.25-1.01]; p =

257 2.6), dyspepsia (RR, 3.3; 95%, 1.4-7.7), and constipation (RR, 2.2; 95% CI, 1.3-3.7).

258 Studies were included if constipation satisfied the Rome II and or III criteria.

259 In addition, mean constipation scores were significantly higher for the TT

260 e group vs five [19%] in the placebo group), constipation (seven [27%] vs none), and loss of appetite

261 Guided by efficacy and cost, management of constipation should begin with dietary fiber supplementa

262 Studies estimating population prevalence of constipation should use definitions based on the Rome cr

263 activity, occupational solvent exposure, and constipation showed associations with alpha-diversity.

264 ne patch for vivid dreams, insomnia, nausea, constipation, sleepiness, and indigestion.

265 macrogol, fiber and lactulose and for acute constipation sodium picosulfate, bisacodyl and enemas.

266 omic units) and demographic variables, diet, constipation status, colonic transit, and methane produc

267 ut also differences in core symptoms between constipation subtypes of functional constipation and irr

268 This review aimed to describe core constipation symptoms and their frequency patterns among

269 In general, Asian adults perceive constipation symptoms in a similar but not equivalent ma

270 It is not known if frequency patterns of constipation symptoms in adults are different between th

271 We aimed to determine the pattern of constipation symptoms in different demographic groups an

272 Finally, we found a range of constipation symptoms, not included in the Rome IV crite

273 ic transit time (CTT), Patient Assessment of Constipation-Symptoms (PAC-SYM), and Patient Assessment

274 At equianalgesic doses, 15au showed less constipation than oxycodone, providing evidence that dua

275 s that TTIL is associated with more pain and constipation than TAMK.

276 In fecal samples from patients with chronic constipation, the microbiota differs from that of health

277 articles of patients with chronic functional constipation, treated with TAI as outpatients and publis

278 e: incidence of adverse events, incidence of constipation, trial withdrawal rate, and patient satisfa

279 [<1%]), hiccups (three [<1%] vs four [<1%]), constipation (two [<1%] vs three [<1%]), and dyspepsia (

280 The most common in the placebo group were constipation (two [2%] patients) and intestinal obstruct

281 of the following symptoms: urinary symptoms, constipation, upper gastrointestinal tract dysfunction,

282 om disease onset to four autonomic symptoms (constipation, urinary symptoms, erectile dysfunction and

283 The risk of postoperative constipation was higher with PN vs. Controls (12.5% vs.

284 Constipation was lowest and subthreshold parkinsonism le

285 an applicable guideline on the management of constipation was poor among pharmacy personnel.

286 Mild-to-moderate constipation was the most common adverse event (in 11% o

287 Constipation was the most common grade 3 or higher adver

288 naire or if constipation/drugs used to treat constipation were coded in patient medical records.

289 Physical inactivity and constipation were highest in individuals with the Firmic

290 he most frequent recommendations for chronic constipation were macrogol, bisacodyl and sodium picosul

291 he most frequent recommendations for chronic constipation were macrogol, fiber and lactulose and for

292 Functional diarrhea and functional constipation were more prevalent by Rome IV than Rome II

293 ea, flatulence, abdominal pain/cramping, and constipation were most common.

294 Urinary symptoms and constipation were present in 81% and 71% of cases, respe

295 s who fulfilled criteria for suspect "occult constipation" were then given a bowel cleaning regimen w

296 veloped more gut aSyn aggregation as well as constipation, whereas FTY720-treated Tg mice had reduced

297 nt benefitting some patients with functional constipation, which is a chronic refractory condition.

298 mergency department with a 1-week history of constipation, which was associated with increasing abdom

299 ndicate that neuron production of 5-HT links constipation with mood dysfunction.

300 The definition used to identify constipation within a population has a considerable impa